We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aravive (ARAV) Flat As Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Aravive (ARAV - Free Report) closed at $11.96, marking no change from the previous day. This move lagged the S&P 500's daily gain of 0.9%. Meanwhile, the Dow gained 0.56%, and the Nasdaq, a tech-heavy index, added 1.13%.
Prior to today's trading, shares of the biopharmaceutical company had gained 101.35% over the past month. This has outpaced the Medical sector's gain of 14.19% and the S&P 500's gain of 14.3% in that time.
ARAV will be looking to display strength as it nears its next earnings release. In that report, analysts expect ARAV to post earnings of -$0.34 per share. This would mark year-over-year growth of 19.05%. Our most recent consensus estimate is calling for quarterly revenue of $1 million, down 41.18% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$1.58 per share and revenue of $4 million. These totals would mark changes of -0.64% and -15.84%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for ARAV. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. ARAV is currently a Zacks Rank #1 (Strong Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 10, putting it in the top 4% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Aravive (ARAV) Flat As Market Gains: What You Should Know
In the latest trading session, Aravive (ARAV - Free Report) closed at $11.96, marking no change from the previous day. This move lagged the S&P 500's daily gain of 0.9%. Meanwhile, the Dow gained 0.56%, and the Nasdaq, a tech-heavy index, added 1.13%.
Prior to today's trading, shares of the biopharmaceutical company had gained 101.35% over the past month. This has outpaced the Medical sector's gain of 14.19% and the S&P 500's gain of 14.3% in that time.
ARAV will be looking to display strength as it nears its next earnings release. In that report, analysts expect ARAV to post earnings of -$0.34 per share. This would mark year-over-year growth of 19.05%. Our most recent consensus estimate is calling for quarterly revenue of $1 million, down 41.18% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$1.58 per share and revenue of $4 million. These totals would mark changes of -0.64% and -15.84%, respectively, from last year.
It is also important to note the recent changes to analyst estimates for ARAV. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. ARAV is currently a Zacks Rank #1 (Strong Buy).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 10, putting it in the top 4% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.